FEEL THE POWER Investor Presentation | November 2024 1 SAFE HARBOR STATEMENTS Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected impr ...

3Q 2024 Investor Presentation April 2024 © Cal-Maine Foods. All rights reserved. SECTION 1 Company Overview 2 Forward-looking statements and use of non-GAAP financial measures Forward‐Looking and Cautionary Statements This report contains numerous forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act") relating to our shell egg and egg products business, including estimated f ...

Company Overview - Cal-Maine Foods is the 1 U S producer and distributor of fresh shell eggs [7] - The company's mission is to be the most sustainable producer and reliable supplier of fresh eggs and egg products [8] - Cal-Maine Foods has competitive advantages including operational expertise, vertically integrated operations, quality product choice, a disciplined balance sheet, and blue-chip customers [12, 13] Market Dynamics and Strategy - The company maintains a leading production scale, supported by best-in-class operating expertise, with 75% more layer hens than its nearest U S competitor [22] - Cal-Maine Foods has a diversified customer base, with 34% of revenue from its top 3 customers and 49% from its largest customer as of FY2024 [25] - The company is committed to sustainability principles, with over 59 million dozen eggs donated since FY19 [31, 32] - The company's strategy is designed to benefit from higher markets and mitigate the impact of lower markets by efficiently managing costs and maintaining a strong balance sheet [34] - 10 U S states have passed cage-free legislation or regulation for implementation by 2030, expecting ~27% households to be in cage-free states by 2030 [46] Financial Performance and Capital Allocation - The company sold 285 million dozens of eggs in Q4 2024 and 11 billion in FY 2024 [126] - Cal-Maine Foods has a variable dividend policy, allocating one-third of net income for dividend payments, with $782 million in total dividends paid since FY2000 [90, 91] - The company is increasing cage-free capacity through organic and inorganic investments, with spent and committed cage-free capex allocation as of the end of FY 2024 [99] - The company acquired ISE America, Inc commercial shell egg production and processing assets for $112 million, including 1 million cage-free layer hens and 12 million pullets [110]

1Q 2025 Investor Presentation October 2024 © Cal-Maine Foods. All rights reserved. SECTION 1 Company Overview 2 CAL-MAINE FOODS | INVESTOR PRESENTATION | OCTOBER 2024 3 3 Forward-looking statements and use of non-GAAP financial measures Forward‐Looking and Cautionary Statements This report contains numerous forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act") relating to o ...

Company Overview - Cal-Maine Foods is the 1 U S producer and distributor of fresh eggs[6] - The company has a diversified customer base, with 34% of revenue from its largest customer and 49% from its top 3 customers as of FY24[22] - Cal-Maine's operating footprint includes 27 feed mills, 3 breeding facilities, 2 hatcheries, 49 production facilities, 49 processing & packaging facilities, and 5 egg product facilities[19] Market Dynamics and Strategy - Approximately 27% of U S households are expected to be in cage-free states by 2030, driving a shift in production[48] - Conventional eggs maintain a leading retail market share, accounting for 56% of dozens sold by volume in FYTD 25[59] - The company is focused on operational excellence, adapting to changing consumer demand, and responsible capital allocation[71, 73, 75] Financial Performance and Capital Allocation - Cal-Maine reported net income of $219064 million in Q2 2025[145] - The company has paid a total of $905 million in dividends since FY2000[96] - From FY 2022 to FY 2025 (YTD), Cal-Maine allocated $438 million to dividends, $122 million to maintenance CapEx, $251 million to organic growth, $203 million to inorganic growth, and $51 million to ready-to-eat products[103] Acquisitions and Growth - Cal-Maine acquired ISE America, Inc for $112 million, increasing cage-free capacity by 1 million cage-free laying hens[115] - The company has completed 25 acquisitions through Q2 2025[113]

Company Overview - Cal-Maine Foods is the number one U S producer and distributor of fresh eggs [10] - The company's mission is to be the most sustainable producer and reliable supplier of consistent, high-quality fresh eggs and egg products in the United States [13] - Cal-Maine Foods has a premier diverse, integrated asset base, including 29 feed mills, 2 breeding facilities, 2 hatcheries, 49 production facilities, 49 processing & packaging facilities, and 5 egg product facilities [24] - The company has a capacity of approximately 81 million eggs per hour [24] - Shell eggs account for 953% of Cal-Maine Foods' total revenue [26] Market Dynamics and Strategies - 97% of U S households purchase eggs [44] - 71% of U S consumers are increasing protein intake [60] - Conventional eggs maintain a leading retail market share [70] - The top five producers own approximately 37% of the U S layer hen flock [73] Financial Performance and Capital Allocation - Cal-Maine Foods' net income for FYTD Q3 2025 is $878 million [38] - The company has paid over $292 million in dividends since FY2000 [103] - Cal-Maine Foods is acquiring Echo Lake Foods for $258 million Enterprise Value [122]

Investor Presentation November 2023 © Cal-Maine Foods. All rights reserved. SECTION 1 Company Overview CAL-MAINE FOODS | INVESTOR PRESENTATION | NOVEMBER 2023 2 Forward-looking statements and use of non-GAAP financial measures Forward‐Looking and Cautionary Statements This report contains numerous forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act") relating to our shell e ...

(Z)-endoxifen's Potential & Differentiation - (Z)-endoxifen is a novel, next-generation anti-estrogen with best-in-class potential across the breast cancer treatment paradigm[8] - (Z)-endoxifen is potentially a superior ER antagonist, being 100-fold more potent vs other SERMs, and demonstrates superior antitumor efficacy in preclinical and clinical studies[7] - (Z)-endoxifen inhibits clinically relevant ESR1 mutants, an acquired resistance mechanism to aromatase inhibitors[7] - (Z)-endoxifen has the potential to avoid current negative "on target off tissue" effects, potentially improving safety & tolerability and adherence[7] Clinical Trial Results & Regulatory Path - In a Phase II trial, CDK4/6 inhibitor-naïve patients had improved Progression-Free Survival (PFS) with (Z)-endoxifen compared to tamoxifen, with median PFS of 7.2 months versus 2.4 months, HR=0.42 (95% CI 0.22-0.80), Log rank test P=0.002[12] - The KARISMA trial showed a 17.3 percentage point reduction (p<0.01) in mammographic breast density with 1 mg of (Z)-endoxifen compared to a minimal change in the placebo group of 0.27 percentage points[13] - In an ongoing neoadjuvant clinical study, (Z)-endoxifen has demonstrated promising early efficacy with 1 CR and multiple PRs[14] Financials - The company's research and development expenses were $14.117 million in 2024, compared to $17.334 million in 2023[21] - The company's general and administrative expenses were $13.504 million in 2024, compared to $14.043 million in 2023[21] - The company's net loss was $(25.504) million in 2024, compared to $(30.094) million in 2023[21]

Financial Performance - First Busey Corporation's total assets were $119 billion as of March 31, 2024 [3] - The company's Assets Under Care (AUC) reached $128 billion [3] - Last Twelve Months (LTM) revenue totaled $3727 million [4] - FirsTech, a segment of First Busey, processed $11 billion in payments LTM [3] and generated $231 million in revenue LTM [4] - Wealth Management segment revenue LTM was $586 million [4] Balance Sheet & Capital - As of March 31, 2024, the CET1 ratio was 135% and the Total Capital Ratio was 179% [20] - Core deposits represented 967% of total deposits [20] - The loan-to-deposit ratio stood at 762% [26] Wealth Management - Wealth Management's Assets Under Care (AUC) reached $128 billion as of March 31, 2024, a year-over-year increase of 139% [3, 49] - Wealth segment revenue for 1Q24 was $157 million, a year-over-year increase of 53% [49] FirsTech - FirsTech's revenue for 1Q24 reached $60 million, marking the highest quarterly revenue in the company's history [52] - FirsTech is focused on achieving double-digit annual growth and reaching $50 million in annual revenue [54] Strategic Initiatives - On April 1, 2024, First Busey completed the acquisition of M&M Bank Corp [3, 12]

Financial Performance - Q3 FY25 - Enerpac Tool Group's net sales for Q3 FY25 were $159 million, a 5.5% increase compared to $150 million in Q3 FY24[5] - Organic growth for Enerpac Tool Group was 2.0% in Q3 FY25[5] - Industrial Tools & Service (IT&S) net sales were $153 million in Q3 FY25, up 5.1% from $146 million in Q3 FY24, with organic growth of 1.5%[5] - Adjusted EBITDA was $41 million, a 3% increase year-over-year[12] - Adjusted EPS was $0.51, a 9% increase year-over-year[12] Segment Performance - Q3 FY25 - IT&S Product sales were $124 million, a 5.6% increase with 1.0% organic growth[5] - IT&S Service sales were $29 million, a 3.1% increase with 3.4% organic growth[5] - Other (Cortland Biomedical) sales were $5 million, an 18.7% increase[5] Profitability - Q3 FY25 - Gross margin was 50.4%, a decrease of 140 bps year-over-year[12] - Adjusted SG&A was 25.5% of sales, a decrease of 160 bps year-over-year[12] - Adjusted EBITDA margin was 25.9%, a decrease of 50 bps year-over-year[12] FY25 Guidance - The company expects to deliver towards the lower half of the range on Sales, Adjusted EBITDA, and Free Cash Flow[14] - Net sales are projected to be $610 million to $625 million, with 0-2% organic growth and 3-6% total growth[15] - Adjusted EBITDA is projected to be $150 million to $160 million[15] - Free cash flow is projected to be $85 million to $95 million[15]